All In Biotech

Free tool

FAERS Monitor: Primaquine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 008316 or its brand name (Primaquine, Primaquine Phosphate). Reports on generic versions are filed under their own applications.

Reports

87

Serious

76

87% of reports

Hospitalization

30

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • methaemoglobinaemia20
  • drug ineffective13
  • drug interaction12
  • pyrexia10
  • cyanosis8
  • plasmodium vivax infection7
  • chromaturia6
  • dyspnoea6
  • off label use6
  • drug eruption5
  • headache5
  • hyponatraemia4
  • neutropenia4
  • syncope4
  • decreased appetite3

Reports by year received

View as table
YearReports
20044
20051
20101
20123
20137
20142
20153
20162
20173
20185
20197
20201
202133
20229
20231
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,072 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
plasmodium vivax infectionSignal7105875.444668.9444,536
methaemoglobinaemiaSignal202107.11431.239,681
cyanosisSignal8123.063.6850
drug eruptionSignal568.229.1268
chromaturiaSignal664.329.7313
drug interactionSignal1218.310.8181
hyponatraemiaSignal417.26.646
syncopeSignal49.73.723
neutropeniaSignal47.12.715
pyrexiaSignal107.03.946
decreased appetite33.11.02
dyspnoeaSignal62.61.24
drug ineffectiveSignal132.41.410
headache51.90.81
off label use61.70.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.